Journalartikel
Autorenliste: Schmeiser, T.; Mueller-Ladner, U.
Jahr der Veröffentlichung: 2010
Seiten: 653-656
Zeitschrift: Zeitschrift für Rheumatologie
Bandnummer: 69
Heftnummer: 7
ISSN: 0340-1855
DOI Link: https://doi.org/10.1007/s00393-010-0629-x
Verlag: Springer
Abstract:
Certolizumab pegol is a new anti-TNF-alpha inhibitor which has been approved for the treatment of rheumatoid arthritis since October 2009. Due to the modification of the antibody fragment by the adherence of polyethylene glycol (PEG) a sufficient distribution in inflammatory tissue was found in animal experiments. In two individual case reports a remission of therapy refractive arthritis was achieved by administration of certolizumab pegol.
Zitierstile
Harvard-Zitierstil: Schmeiser, T. and Mueller-Ladner, U. (2010) Treatment of patients with destructive arthritis with certolizumab pegol, Zeitschrift für Rheumatologie, 69(7), pp. 653-656. https://doi.org/10.1007/s00393-010-0629-x
APA-Zitierstil: Schmeiser, T., & Mueller-Ladner, U. (2010). Treatment of patients with destructive arthritis with certolizumab pegol. Zeitschrift für Rheumatologie. 69(7), 653-656. https://doi.org/10.1007/s00393-010-0629-x
Schlagwörter
adalimumab; ALPHA MONOCLONAL-ANTIBODY; ANTITUMOR NECROSIS FACTOR; CERTOLIZUMAB PEGOL; DOUBLE-BLIND; Enteropathic arthritis; FUSION PROTEIN; PHASE-III; PLACEBO; RECEIVING CONCOMITANT METHOTREXATE; Refractory arthritis; RHEUMATOID-ARTHRITIS
